代謝機能障害関連脂肪性肝疾患患者における代謝指数の診断性能の比較:後ろ向き横断研究
Ehsan Bahrami Hezaveh1, Rana Hashemi1, Mohammadamin Noorafrooz1
1Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, Imam Khomeini Hospital Complex (IKHC), Tehran University of Medical Sciences, Tehran, Iran.
Background:
Metabolic dysfunction-associated fatty liver disease (MAFLD) has emerged as the leading cause of liver dysfunction and poses a significant risk for progression to cirrhosis. In this study, we aimed to compare the ability of various metabolic indices and identify those most effective for the prediction of MAFLD.
Methods:
This cross-sectional study included 1471 patients (69.6% MAFLD) between 2011 and 2024. Specific metabolic indices were calculated. The associations between indices and MAFLD were analyzed via logistic regression analysis and restricted cubic splines. The prediction ability of the indices was evaluated via receiver operating characteristic (ROC) analysis in different subgroups.
Results:
Triglyceride glucose (TyG) index, homeostatic model assessment for insulin resistance (HOMA-IR), and estimated glucose disposal rate (eGDR) had the strongest associations with MAFLD (final adjusted ORs for TyG = 3.60, HOMA-IR = 3.35, eGDR = 2.97 per unit change). According to the ROC curve analysis, TyG index and hepatic steatosis index (HSI) had the highest area under the curve (AUC) for the prediction of MAFLD in females (AUC = 0.832) and males (AUC = 0.848), respectively. TyG also performed the best in lean/normal-weight and overweight/obesity individuals, with AUCs of 0.890 and 0.787, respectively. TyG in those ≥ 65 years old (AUC = 0.844) and eGDR in those < 65 years old (AUC = 0.843) had the highest prediction performance for MAFLD.
Conclusion:
Insulin resistance markers, including TyG, HOMA-IR, and eGDR, had the strongest associations with MAFLD. For predicting MAFLD, TyG had the highest performance across all subgroups, except for males and those < 65 years, where HSI and eGDR performed better, respectively.
さらに関連する動画
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
08:41Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
関連する概念動画
Overview of Fatty Acid Metabolism
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
What is Metabolism?
Cross-Sectional Research
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
